US20230348599A1
University of Texas System
The current disclosure provides for novel therapeutic methods by identifying glioblastoma patient populations that may be treated effectively by immunotherapies. Also provided are therapies that may be used in combination of immune checkpoint therapy (ICB) to increase the effectiveness of the …